

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

OMB Number:	3235-0287
Estimated average burden	
hours per response:	0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

☐ Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

☐ Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person *	2. Issuer Name and Ticker or Trading Symbol	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)
<u>Hippel James</u>	<u>BIO-TECHNE Corp [TECH]</u>	Director 10% Owner
(Last) (First) (Middle)	3. Date of Earliest Transaction (Month/Day/Year)	☒ Officer (give title below) Other (specify below)
<u>614 MCKINLEY PLACE NE</u>	<u>08/15/2026</u>	<u>CFO</u>
(Street)	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line)
<u>MINNEAPOLIS MN 55413</u>		☒ Form filed by One Reporting Person
(City) (State) (Zip)		Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	08/15/2026		M		9,779	A	\$0	174,493	D	
Common Stock	08/15/2026		F		4,310	D	\$72.4	170,183	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Options (Right to Buy)	\$66.97							(1) 08/05/2027		Common Stock	167,328		167,328	D	
Stock Options (Right to Buy)	\$120.46							(1) 08/06/2028		Common Stock	40,536		40,536	D	
Stock Options (Right to Buy)	\$94.52							(1) 08/15/2029		Common Stock	45,220		45,220	D	
Performance Restricted Stock Units	(2)	08/15/2026		M			866	(3) (3)		Common Stock	866	\$0	12,999	D	
Performance Restricted Stock Units	(2)	08/15/2026		D			12,999	(3) (3)		Common Stock	12,999	\$0	0	D	
Performance Stock Options (Right to Buy)	\$84.61	08/15/2026		D			34,982	(4) 08/15/2030		Common Stock	34,982	\$0	2,332	D	
Stock Options (Right to Buy)	\$84.61							(5) 08/15/2030		Common Stock	45,923		45,923	D	
Performance Restricted Stock Units	(2)							(6) (6)		Common Stock	24,062		24,062	D	

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Restricted Stock Units	(2)	08/15/2026		M			4,010	(7)	(7)	Common Stock	4,010	\$0	4,011	D	
Stock Options (Right to Buy)	\$74.91							(8)	08/15/2034	Common Stock	32,417		32,417	D	
Restricted Stock Units	(2)							(9)	(9)	Common Stock	23,089		23,089	D	
Performance Restricted Stock Units	(2)							(10)	(10)	Common Stock	29,420		29,420	D	
Restricted Stock Units	(2)	08/15/2026		M			4,903	(11)	(11)	Common Stock	4,903	\$0	9,807	D	
Stock Options (Right to Buy)	\$53.6							(12)	08/15/2035	Common Stock	37,632		37,632	D	

Explanation of Responses:

1. Fully exercisable.
2. Each restricted stock unit represents a contingent right to receive one share of Bio-Techne Corporation common stock.
3. On 8/15/2026, the Board of Directors authorized discretionary vesting for 866 performance RSUs. The remainder of the performance RSUs were forfeited.
4. On 8/15/2026, the Board of Directors authorized discretionary vesting for 2,332 performance options. The remainder of the performance options were forfeited.
5. Options to purchase 11,481 shares vest on each of 8/15/2024, 8/15/2025 and 8/15/2027, and options to purchase 11,480 shares vest on 8/15/2026.
6. Vests in full or in part on 8/15/2027 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
7. 4,010 restricted stock units vest on 8/15/2026; and 4,011 restricted stock units vest on 8/15/2027.
8. Options to purchase 8,104 shares vest on each of 8/15/2025, 8/15/2026 and 8/15/2027, and options to purchase 8,105 shares vest on 8/15/2028.
9. 11,545 restricted stock units vest on 11/1/2026; and 11,544 restricted stock units vest on 11/1/2027.
10. Vests in full or in part on 8/15/2028 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
11. 4,903 restricted stock units vest on each of 8/15/2026 and 8/15/2027, and 4,904 restricted stock units vest on 8/15/2028.
12. Options to purchase 12,544 shares vest on each of 8/15/2026, 8/15/2027 and 8/15/2028.

/s/ Andrew Nick as Attorney-in-Fact for James Hippel pursuant to 08/18/2026 Power of Attorney previously filed

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.